Predicting Survival in Pulmonary Arterial Hypertension Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)

被引:1247
作者
Benza, Raymond L. [1 ]
Miller, Dave P. [2 ]
Gomberg-Maitland, Mardi [3 ]
Frantz, Robert P. [4 ]
Foreman, Aimee J. [2 ]
Coffey, Christopher S. [5 ]
Frost, Adaani [6 ]
Barst, Robyn J. [7 ]
Badesch, David B. [8 ]
Elliott, C. Gregory [9 ,10 ]
Liou, Theodore G. [10 ]
McGoon, Michael D. [4 ]
机构
[1] Allegheny Gen Hosp, Gerald McGinnis Cardiovasc Inst, Pittsburgh, PA 15212 USA
[2] ICON Clin Res, San Francisco, CA USA
[3] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[4] Mayo Clin, Rochester, MN USA
[5] Univ Alabama Birmingham, Birmingham, AL USA
[6] Baylor Coll Med, Houston, TX 77030 USA
[7] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA
[8] Univ Colorado, Denver, CO 80202 USA
[9] Intermt Med Ctr, Salt Lake City, UT USA
[10] Univ Utah, Salt Lake City, UT USA
关键词
prognosis; pulmonary arterial hypertension; risk factors; survival; CALCIUM-CHANNEL BLOCKERS; HEMODYNAMICS; METAANALYSIS; OUTCOMES; TRIALS; MODEL;
D O I
10.1161/CIRCULATIONAHA.109.898122
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Factors that determine survival in pulmonary arterial hypertension (PAH) drive clinical management. A quantitative survival prediction tool has not been established for research or clinical use. Methods and Results-Data from 2716 patients with PAH enrolled consecutively in the US Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) were analyzed to assess predictors of 1-year survival. We identified independent prognosticators of survival and derived a multivariable, weighted risk formula for clinical use. One-year survival from the date of enrollment was 91.0% (95% confidence interval [CI], 89.9 to 92.1). In a multivariable analysis with Cox proportional hazards, variables independently associated with increased mortality included pulmonary vascular resistance >32 Wood units (hazard ratio [HR], 4.1; 95% CI, 2.0 to 8.3), PAH associated with portal hypertension (HR, 3.6; 95% CI, 2.4 to 5.4), modified New York Heart Association/World Health Organization functional class IV (HR, 3.1; 95% CI, 2.2 to 4.4), men >60 years of age (HR, 2.2; 95% CI, 1.6 to 3.0), and family history of PAH (HR, 2.2; 95% CI, 1.2 to 4.0). Renal insufficiency, PAH associated with connective tissue disease, functional class III, mean right atrial pressure, resting systolic blood pressure and heart rate, 6-minute walk distance, brain natriuretic peptide, percent predicted carbon monoxide diffusing capacity, and pericardial effusion on echocardiogram all predicted mortality. Based on these multivariable analyses, a prognostic equation was derived and validated by bootstrapping technique. Conclusions-We identified key predictors of survival based on the patient's most recent evaluation and formulated a contemporary prognostic equation. Use of this tool may allow the individualization and optimization of therapeutic strategies. Serial follow-up and reassessment are warranted.
引用
收藏
页码:164 / U138
页数:27
相关论文
共 25 条
[1]   Medical therapy for pulmonary arterial hypertension - Updated ACCP evidence-based clinical practice guidelines [J].
Badesch, David B. ;
Abman, Steven H. ;
Simonneau, Gerald ;
Rubin, Lewis J. ;
McLaughlin, Vallerie V. .
CHEST, 2007, 131 (06) :1917-1928
[2]   SURVIVAL IN PATIENTS WITH PRIMARY PULMONARY-HYPERTENSION - RESULTS FROM A NATIONAL PROSPECTIVE REGISTRY [J].
DALONZO, GE ;
BARST, RJ ;
AYRES, SM ;
BERGOFSKY, EH ;
BRUNDAGE, BH ;
DETRE, KM ;
FISHMAN, AP ;
GOLDRING, RM ;
GROVES, BM ;
KERNIS, JT ;
LEVY, PS ;
PIETRA, GG ;
REID, LM ;
REEVES, JT ;
RICH, S ;
VREIM, CE ;
WILLIAMS, GW ;
WU, M .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (05) :343-349
[4]   A meta-analysis of randomized controlled trials in pulmonary arterial hypertension [J].
Galie, Nazzareno ;
Manes, Alessandra ;
Negro, Luca ;
Palazzini, Massimiliano ;
Bacchi-Reggiani, Maria Letizia ;
Branzi, Angelo .
EUROPEAN HEART JOURNAL, 2009, 30 (04) :394-403
[5]  
Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO
[6]  
2-4
[7]   Pulmonary arterial hypertension in France - Results from a national registry [J].
Humbert, M ;
Sitbon, O ;
Chaouat, A ;
Bertocchi, M ;
Habib, G ;
Gressin, V ;
Yaici, A ;
Weitzenblum, E ;
Cordier, JFO ;
Chabot, F ;
Dromer, C ;
Pison, C ;
Reynaud-Gaubert, M ;
Haloun, A ;
Laurent, M ;
Hachulla, E ;
Simonneau, G .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2006, 173 (09) :1023-1030
[8]   Hemodynamics and survival of patients with portopulmonary hypertension [J].
Kawut, SM ;
Taichman, DB ;
Ahya, VN ;
Kaplan, S ;
Archer-Chicko, CL ;
Kimmel, SE ;
Palevsky, HI .
LIVER TRANSPLANTATION, 2005, 11 (09) :1107-1111
[10]  
Kung Hsiang-Ching, 2008, Natl Vital Stat Rep, V56, P1